GlobalData on MSN22h
BioNTech signs agreement to acquire Biotheus
BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
BioNTech Boosts Oncology Strategy With $800 Million+ China-Based Biotheus Acquisition
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
BioNTech to Acquire Biotheus for $800 Million to Expand Oncology Portfolio
BioNTech SE ( BNTX, Financials) announced plans to acquire Biotheus, a clinical-stage biotechnology company, for $800 million ...
Pharmabiz59m
BioNTech to acquire clinical-stage biotech company, Biotheus to boost oncology strategy
BioNTech SE and Biotheus (Biotheus) announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development ...
BioPharma Dive1d
BioNTech to buy Biotheus, gaining control of cancer bispecific
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
pharmaphorum1d
BioNTech buys Biotheus and its Keytruda rival for $950m
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...
BioNTech signs agreement to acquire Biotheus to enhance tumor treatment capabilities
BioNTech, the German pharmaceutical company, announced on Wednesday that it has reached an agreement to acquire Biotheus, a ...
BioNTech To Buy Biotheus In Upfront Payment Of $800 Mln
BioNTech SE (BNTX) announced Tuesday that it has signed an agreement to acquire Biotheus, a clinical-stage biotechnology company ...
MM&M1d
BioNTech spends $800M upfront to pick up China-based Biotheus
BioNTech is investing in a promising space in oncology by acquiring Biotheus’ PD-L1 and VEGF bispecific antibody.
Business Insider1d
BioNTech to acquire Biotheus for upfront consideration of $800M
BioNTech (BNTX) and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel ...
MarketWatch1d
BioNTech to Acquire Biotheus in $950 Million Deal
BioNTech has agreed to acquire biotechnology company Biotheus for $800 million up front and up to $150 million in milestone payments. The German developer of RNA vaccines and immunotherapies said ...